Navigation Links
Decision Resources' Updated Rheumatoid Arthritis Report Now Includes Forecast for Rigel Pharmaceuticals' Fostamatinib Disodium
Date:8/6/2009

WALTHAM, Mass., Aug. 6 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, today released its updated Pharmacor Rheumatoid Arthritis report which now includes patient share and sales forecasts through 2018 for Rigel Pharmaceuticals' investigational novel oral agent, fostamatinib disodium (R788). The report update is based on Rigel Pharmaceuticals' recent announcement regarding additional Phase II clinical data for fostamatinib disodium.

The report finds that, owing to its impressive efficacy, the spleen tyrosine kinase (Syk) inhibitor fostamatinib disodium will likely precede TNF-alpha inhibitors such as Amgen/Wyeth/Takeda's Enbrel and Abbott/Eisai's Humira in the treatment cascade for rheumatoid arthritis. Phase II data shows that fostamatinib disodium's efficacy is comparable to that of currently-available biologic agents in patients with inadequate response to treatment with methotrexate. According to the report, if the agent is priced lower than currently-available biologics, physicians may be willing to prescribe fostamatinib disodium as an alternative to premium-priced biologics.

However, Decision Resources conservatively forecasts that fostamatinib disodium's patient share will reach up to 1.8 percent and it will garner major-market sales of $330 million in 2018.

"Fostamatinib disodium's patient share and sales will be considerably lower than our evaluation of the other novel oral agent in development for rheumatoid arthritis--Pfizer's Jak-3 inhibitor CP-690550," said Decision Resources Analyst Joanna Kim, M.Ed. "Fostamatinib disodium's impact is likely to be less than that of CP-690550 because of uncertainties about its efficacy in the TNF-refractory population and the absence of a head-to-head trial against a TNF-alpha inhibitor."

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                         Decision Resources, Inc.
    Christopher Comfort                        Elizabeth Marshall
    781-296-2597                               781-296-2563
    ccomfort@dresources.com                    emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. BCBSGA Announces Decision to Cover H1N1 Vaccine Administration
2. PET can help guide treatment decisions for a common pediatric cancer
3. WellPoint Announces Decision to Cover H1N1 Vaccine Administration
4. United States Patent Office Issues Decision in Re-examination Proceedings
5. Providence Service Corporation Comments on U.S. Court of Appeals Decision to Uphold Federal Injunction Blocking Californias 10% Cut in Medi-Cal Payments
6. Stem Cell Decision Opens New Doors, May Spur More Research
7. TriServ Likely to Protest Decision
8. Communicating science to decision makers
9. Brain section multitasks, handling phonetics and decision-making
10. The decision about the incision: Is midline or transverse better for abdominal surgery?
11. Jeff Stewart Joins Decision Resources, Inc. as Chief Information Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... FLORIDA (PRWEB) , ... April 24, 2017 , ... ... telehealth technology yesterday, featuring Bring Your Own Device (BYOD) capabilities at Telehealth 2.0, ... LG CNS’ pre-packaged telehealth bundles, which pairs medical devices with a pre-programmed tablet ...
(Date:4/24/2017)... ... April 24, 2017 , ... Ridgecrest Herbals makes it a point to lead ... reduce waste, and support renewable energy. They believe this is a crucial part of ... solutions for health issues, and maintain that destroying the environment in the pursuit of ...
(Date:4/24/2017)... ... , ... The bar for just about everything—apparel, eyewear, cars and even phone ... pop and film stardom.(1) Not to be left out is that most desired of ... the gamut from being encrusted with jewels and precious metals to, at the very ...
(Date:4/24/2017)... Seattle, Washington (PRWEB) , ... April 24, 2017 , ... ... T-Fal OptiGrill, Oxiclean, Space Bag, Sonicare Toothbrush, Juiceman Juicer, and the George Foreman Grill ... than perhaps any other marketer in the last 25 years. , Now, due to ...
(Date:4/24/2017)... , ... April 24, 2017 , ... ... of unique liquid food supplements, announced its popular products are now available for ... , ALP Nutrition® prioritizes the use of premium natural ingredients in making all ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... 19, 2017 Cardiology devices segment is anticipated to ... The Cardiology Devices segment is likely to create absolute ... in 2018 over 2017. By the end of 2027, Cardiology ... to US$ 700 Mn, expanding at a CAGR of 18.4% ... Asia Pacific reprocessed medical devices market ...
(Date:4/19/2017)... Global Prostate Cancer Therapeutics Market: Overview ... cancer therapeutics market analyzes the current and future ... prostate cancer, launch of promising emerging therapies, as ... drugs & therapeutic biological products, and high growth ... side effects are some of the drivers expected ...
(Date:4/19/2017)... , April 19, 2017 ... an immune response in pets such as canine, ... are of various types such as Attenuated Live ... Vaccines, DNA Vaccines and Recombinant Vaccines. Attenuated live ... virus or bacteria, which have been weakend under ...
Breaking Medicine Technology: